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In the present preliminary study we explored the possibility of an anticonvulsant effect of normal human 
immunoglobulin in an animal epilepsy model based on direct cortical stimulation in freely moving rats. After 
human immunoglobulin administration a significant and prolonged elevation of the threshold for convulsions was 
measured in 12% (6/49) of the total group of outbred Wistar rats. In the subgroup of more than seven months old 
Wistar rats this was 67% (6/9). When a threshold increasing effect of immunoglobulin occurred, it was detectable 
within 0.5-l hour after administration, reached its maximum after approximately two hours and continued for at 
least 40 hours. 
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INTRODUCTION 
Normal human immunoglobulin (IVIg) initially 
used for substitution of immunodeficiency syndr- 
omes has recently been reported to be effective in 
an increasing amount of diseases thought to be 
produced by immunopathology’**. Although epi- 
Iepsy is one of the oldest applications of IVIg in 
neurological diseases3, and although positive 
results have been published, IVIg treatment of 
intractable epilepsies, nevertheless, remains 
controversia14: on the one side the various studies 
on IVIg in human epilepsy could not provide an 
indication for an immunological mechanism of 
action of IVIg4, on the other side it has been 
stated without published data that IVIg lacks an 
anticonvulsant effect?. In the present study we 
explored the possibility of an anticonvulsant 
effect of IVIg in an animal epilepsy model based 
on direct cortical stimulation in freely moving 
rats6*‘. In the subgroup in which IVIg was 
ineffective we investigated whether this was due 
to an inability of IVIg to cross the blood-brain 
barrier. 
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MATERIALS AND METHODS 
Female (outbred) Wistar rats of 175200g were 
purchased from Harlan/CPB in Zeist, The 
Netherlands. They were housed’ individually in 
plastic cages, at constant temperature (21”C), and 
in controlled lighting (light period 7.00 a.m. to 
7.00 p.m.). Food (standard laboratory rat, mouse, 
and hamster diets, R.M.H.-T.M., Hope Farms, 
Woerden, The Netherlands) and water were 
supplied ad libitum, except during actual testing. 
Forty-nine rats were used conforming to institu- 
tional policies and guidelines. 
Human IVIg was produced from the plasma of 
more than 3000 Dutch blood donors by ethanol 
fractionation, treated at pH 4 with a low con- 
centration of pepsin (Central Laboratory of the 
Netherlands Red Cross Blood Transfusion 
Service, Amsterdam, NL). IVIg dissolved in 
sterile water without solvents contains 99% IgG, 
1% IgA and traces of IgM. Its osmolarity is 
equivalent to that of plasma, with a sodium 
concentration between 25 and 5Ommol/l, and a 
glucose concentration between 160 and 
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300 mmol/l. No mannitol or glycine is added in 
this IVIg preparation. IVIg was administered in a 
comparable dosage as in humans (400-1000- 
15OOmg/kg body/weight), but by a different 
route, i.e. by a single intraperitoneal (i.p.) 
dose. 
The anticonvulsant efficacy was tested and 
quantified using direct cortical stimulation with a 
ramp-shaped pulse train as described in detail 
elsewhere-. The threshold for localized seizure 
activity (TLS) has been used to quantify anticon- 
vulsant effects. The TLS was defined as the 
current at which the first mild clonic forepaw 
movements appeared. TLS stimulation was 
stopped at this point and further convulsive 
activity was then immediately aborted. In this 
way a postictal threshold increase was avoided. 
Before IVIg administration, the TLS was deter- 
mined five times at five minute intervals, to 
determine the average baseline value. Shortly 
after i.p. IVIg injection, TLS determination was 
performed, and during three days the TLS was 
measured at regular intervals. TLS changes were 
expressed as elevation over the baseline value in 
PA. All test sessions were recorded on video. 
Before IVIg experiments were carried out, the 
animals were tested twice daily for two weeks to 
stabilize the threshold’. The effect of IVIg on TLS 
was tested in more than seven months old rats 
(n = 9), and in younger rats (3-4.5 months, 
n = 40). Some rats of the younger age group 
(n = 10) were treated previously with car- 
bamazepine (40 mg/kg), others (n = 30) were 
drug-naive. 
In addition, we investigated (n = 3) whether 
IVIg was ineffective due to an inability to cross 
the blood-brain barrier: two days after IVIg 
administration rates were killed, and brains were 
freshly fixed in formaldehyde-sublimate at 4°C for 
24 hours. After dehydration tissue was embedded 
in paraplast and four micron sections were cut 
using a Jung 2050 microtome. Dewaxed poly-L- 
lysine mounted sections were incubated with 
human IgG antiserum (gamma chain specific, 
Dakopatts) for 48 hours at 4°C in a dilution of 
l/250. Immunohistochemical staining was per- 
formed using the avidin-biotin-peroxidase and 
the avidin-biotin-alkaline-phosphatase complex 
technique (ABC) according to the manufacturer 
instructions (Vector). All antibody dilutions were 
made in 0.05 M phosphate buffered saline (PBS) 
to which 0.1% Triton-X-100 was added. As 
negative controls we used rats (n = 3) that 
also had experienced seizures due to cortical 
stimulation but without administration of human 
IVIg. 
RESULTS 
After human immunoglobulin administration 
(500 mg/kg; Table 1) a significant and longlasting 
increase in TLS was measured in 12% (6/49) of 
the total group of outbred Wistar rats. In the 
subgroup of more than seven months old Wistar 
rats this was 67% (6/9), in the other subgroup this 
was 0% (O/40) (Fisher exact test (P <O.OOOl), 
Table 1). Figure 1 depicts the typical time-effect 
relationship in an animal showing an increase in 
TLS. When a TLS increasing effect of IVIg 
occurred, it was detectable within 0.5-l hour 
after administration, reached its maximum after 
approximately two hours and continued for at 
least 40 hours. 
In the subgroup (n = 40) of 3-4.5 months old 
rats, neither three different doses of IVIg (400, 
1000, 1500mg/kg), nor pretreatment with car- 
bamazepine (40mg/kg) showed any effect on 
TLS. 
In control rats (with cortical stimulation, 
without IVIg treatment) immunohistochemical 
staining for human IgG was negative (Fig. 2a), 
whereas in all (non-responding) rats (n = 3) killed 
two days after IVIg administration, staining for 
human IgG was present in brain capillaries, 
chorioid plexus, and in brain tissue around blood 
vessels (Fig. 2b). Some neuronal and glial cells 
showed immunohistochemical staining. Thus, the 
lack of a threshold increasing effect by IVIg was 
not due to an inability of IgG to cross the 
blood-brain barrier. 
DISCUSSION 
These preliminary investigations indicate that 
human IVIg has the potential to raise the 
threshold for convulsions in rats. Already within 
the first hour after i.p. administration a significant 
and prolonged anticonvulsant effect occurred in 
12% of all tested outbred Wistar rats. In the 
subgroup of more-than-seven-months-old Wistar 
rats this percentage was 67%, which suggests an 
age-related effect of the IVIg response. An 
age-related effect of epilepsy itself has been 
reported previously: seizure intensity increased 
with increasing age in genetically epilepsy-prone 
ratsg. The present study confirmed the results of 
the only other study on administration of human 
IVIg in an animal epilepsy model (kindled cats)“. 
In the latter study and in our study a similar 
time-effect relationship and a similar immunohis- 
tochemical staining pattern for human IgG were 
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Table 1: The effect of human IVlg on the convulsive threshold in rats’ 
Animals Immunoglobulin Results 
Number Age 
(months) 
Dose hdkg) Increase of TLS** 
n=9 >I 500 6 of 9 animals, 200 pA 
(Avg. baseline 400 pA) 
n = 40 3-4.5 400, 1000 or 1500 0 of 40 animals 
* IVIg, Human immunoglobulin; TLS, threshold for localiied seizures. 
** P < 0.0001 by Fisher Exact test. 
seen: IgG penetrated the blood-brain barrier, seizures, duration of epilepsy, immunological 
could be found around the blood vessels, and was abnormalities, or study design4. We cannot 
even taken up by some neuronal and glial cells in exclude that on the clinical level these factors 
the cerebral cortex and deep structures of the contribute to the variable responses, but as can be 
CNS. These findings might be compatible with concluded from the present study, in the more 
reports on blood-brain barrier permeability in controllable animal-model a remarkable age- 
various types of experimental epilepsies”, the related variability in treatment -response was 
existence of IgG Fc receptors in adult rat brain found. Another contributing factor for the 
and in normal human brains12,13, and variability in IVIg response might be genetic 
immunoglobulin affinity of neuronal and glial 
cells’4,‘5. 
heterogeneity in both humans with epilepsy and 
outbred Wistar rats. 
The present experimental data are in ac- 
cordance with the results of clinical studies on 
IVIg in patients with epilepsy. Of the several 
hundreds of IVIg treated patients with otherwise 
intractable epilepsies, overall some 23% showed 
total cessation of seizures4. The variability of IVIg 
treatment effect in human epilepsy is still 
unexplained. It has been attributed to differences 
in IVIg preparations, types of epilepsy and 
In conclusion, we can not confirm that IVIg 
lacks an anticonvulsant effect?. On the contrary, 
this preliminary study suggests the potential of a 
significant and longlasting anticonvulsant effect of 
IVIg by increasing the threshold for convulsions. 
However, future studies are needed and should 
investigate the effect of albumin (as a control) on 
TLS in more than seven-month-old animals, the 
repetitive IVIg administration in IVIg-responding 
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Fig. 1: The effect of 500 mg/kg human IVlg on the threshold for localized seizures (TLS) in eight months old rats who had 
previously experienced generalized seizures and had been treated with carbamazepine. 
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Fig. 2: (a) lmmunohistochemical staining for human IgG was negative in control rats (with cortical stimulation, without IVlg 
treatment). (b) lmmunohistochemical staining for human IgG in rats treated with a single dose of IVlg was present in and around 
cerebral bloodvessels. 
animals, and the capability of IgG to cross the 
blood-brain barrier in IVIg-responding and non- 
responding animals. 
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